🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

iCell Gene Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with iCell Gene Therapeutics as lead sponsor. Synced 26 Sep 2026
6Current trials
5Recruiting now
0Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

iCell Gene Therapeutics is the lead sponsor of 6 current clinical trials in our China and USA registers. 5 are recruiting patients now. The most common phase is Phase 1. The most-studied condition is Systemic Lupus Erythematosus (SLE).

ClinicalTrials.gov trials by status

  • Recruiting583%
  • Not yet open117%

Trials by phase

  • Phase 1467%
  • Phase 2117%
  • Phase 1/2117%
01

Clinical trials sponsored by iCell Gene Therapeutics

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
NCT04162353 · ClinicalTrials.gov ↗ · Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma
Phase 1 Recruiting 2019-07 China
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
NCT06787989 · ClinicalTrials.gov ↗ · Refractory Immune Cytopenia
Phase 1 Recruiting 2024-08 China
Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT07668557 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)
Phase 1 Recruiting 2026-06 China
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
NCT07328581 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Phase 2 Recruiting 2026-09 USA
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
NCT07715136 · ClinicalTrials.gov ↗ · Inflammatory Myopathy
Phase 1 Recruiting 2025-03 China
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
NCT07544160 · ClinicalTrials.gov ↗ · Inflammatory Bowel Diseases (IBD)
Phase 1/2 Not yet open 2026-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in iCell Gene Therapeutics trials

9 conditions
Systemic Lupus Erythematosus (SLE)1Lupus Nephritis (LN)1Multiple Myeloma in Relapse1Refractory Multiple Myeloma1Plasmacytoid; Lymphoma1Refractory Immune Cytopenia1Acute Myeloid Leukemia (AML)1Inflammatory Myopathy1Inflammatory Bowel Diseases (IBD)1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China54
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Systemic Lupus Erythematosus (SLE)

SponsorTrials
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology5
China Immunotech (Beijing) Biotechnology4
Beijing GoBroad Hospital3
EMD Serono Research & Development Institute2
Fate Therapeutics2
Bioray Laboratories2
Nanjing Legend Biotech Co1
Sunshine Guojian Pharmaceutical (Shanghai)1
Candid Therapeutics1
Shanghai Escugen Biotechnology1

Sponsors with the most current trials registered for this condition.

05

Questions about iCell Gene Therapeutics trials

How many clinical trials does iCell Gene Therapeutics sponsor?

iCell Gene Therapeutics is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are iCell Gene Therapeutics trials recruiting?

Yes. 5 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.